4D Pharma (LON: DDDD, NASDAQ: LBPS) said on Tuesday that pre-clinical research conducted in Germany has demonstrated its second-generation immuno-oncology LBP MRx1299 drug works to enhance the anti-tumour activity of cytotoxic T lymphocytes (CTL) and CAR-T therapies.
The research, carried out in collaboration with the Philipps-University Marburg, Universitätsklinikum Würzburg, and published in Nature Communications, was conducted using animal models and resulted in improved tumour clearance.
4D pharma identified M. massiliensis MRx1299 using its MicroRx platform and previously showed “MRx1299 to have specific histone deacetylase (HDAC) inhibitory activity and be a rare prolific producer of pentanoate.”
“Our existing clinical oncology programs, such as the study of MRx0518 and Keytruda in refractory patients, have shown the important role our live biotherapeutics have to play in the fight against cancer in combination with immunotherapies,” commented Dr Imke Mulder, Research Director, 4D Pharma.
“Using the MicroRx platform we have now shown we have the potential to improve the efficacies of cell therapies such as CAR-T.
“This demonstrates not only the importance of Live Biotherapeutics as a new modality poised to revolutionize the treatment of a wide range of cancers, but also the power of our MicroRx platform to continue making significant discoveries and advances in this field,” added Mulder.
4D Pharma's share price rose to a high of 108.6p earlier in Tuesday's session. However, it is currently trading at 10p, up just 0.06%.
Should you invest in 4D Pharma shares?
4D Pharma shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are 4D Pharma shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
